ER36 gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells

被引:11
作者
Wang, Hong-Bin [1 ]
Li, Tao [1 ]
Ma, Dong-Zhou [1 ]
Zhi, Hua [2 ]
机构
[1] Hebei Univ Engn, Affiliated Hosp, Dept Neurosurg, Handan, Peoples R China
[2] Hebei Univ Engn, Affiliated Hosp, Dept Cardiol, 81 Congtai Rd, Handan 056002, Hebei, Peoples R China
关键词
estrogen stimulation; Caveolin-1; GSK-3; PP2A; MAPK pathway; ESTROGEN-RECEPTOR-ALPHA; PHOSPHATASE 2A PP2A; BREAST-CANCER; TUMOR-SUPPRESSOR; EXPRESSION; VARIANT; RECEPTOR-ALPHA-36; DIFFERENTIATION; IDENTIFICATION; ER-ALPHA-36;
D O I
10.1096/fj.201701386
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuroblastoma is the most common cancer in infants and the third most common cancer in children after leukemia and brain cancer. The purpose of our study was to investigate the effects of estrogen receptor (ER)-36 gene silencing on tau protein phosphorylation, cell proliferation, and cell apoptosis in human neuroblastoma SH-SY5Y cells. SH-SY5Y cells were treated with estrogen or left untreated, to investigate the effects of estrogen stimulation on ER36 and the ERK/protein B kinase (AKT) signaling pathway. ER36 mRNA expressions were detected by quantitative RT-PCR. A phosphatase kit was used to test protein phosphatase (PP)-2A activity before and after treatment. Western blot analysis was conducted to detect protein expression of ER36; tau protein; phosphorylated- tau (p-tau) at site Thr231 [p-tau (Thr231)]; glycogen synthase kinase (GSK)3 and its specificity sites (Tyr216 and Ser9); Cyclin Dl; proliferating cell nuclear antigen (PCNA); B-cell lymphoma (Bcl)-2; and Bcl-2-associated X protein (Bax). A cell-counting kit (CCK)-8 assay was used to determine cell viability. Cell apoptosis and rate of tumor growth and volume were determined by Annexin V-FITC/PI staining and a xenotransplanted tumor model in nude mice. Results show that without estrogen stimulation, ER36 was inactivated. When stimulated by estrogen, expression of ER36, PP2A, p-GSK3 (Ser9)/total protein (t)-GSK3, Cyclin Dl, PCNA, and Bcl-2 were up-regulated, and p-GSK3 (Tyr216)/t-GSK3 expression was down-regulated, as was p-tau (Thr231) and Bax expression. The expression of p-ERK/ERK, p-AKT/AKT, p-methyl ethyl ketone (MEK)/MEK, and p-mammalian target of rapamycin (mTOR)/mTOR expression was up-regulated, suggesting that the ERK/AKT signaling pathway is activated. Cell proliferation was also accelerated, whereas apoptosis was inhibited with stimulation by estrogen. However, we found that the effects of silencing ER36 on the expression of related intracellular factors had no association with estrogen. Our study demonstrates that ER36 gene silencing can inhibit the activation of the ERK/AKT signaling pathway, increase tau protein phosphorylation, decrease cell vitality and tumorigenicity, and promote apoptosis of human neuroblastoma SH-SY5Y cells.Wang, H.-B., Li, T., Ma, D.-Z., Zhi, H. ER36 gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells.
引用
收藏
页码:6456 / 6468
页数:13
相关论文
共 44 条
[41]   Opposite effects of two estrogen receptors on tau phosphorylation through disparate effects on the miR-218/PTPA pathway [J].
Xiong, Yan-Si ;
Liu, Fang-Fang ;
Liu, Dan ;
Huang, He-Zhou ;
Wei, Na ;
Tan, Lu ;
Chen, Jian-Guo ;
Man, Heng-Ye ;
Gong, Cheng-Xin ;
Lu, Youming ;
Wang, Jian-Zhi ;
Zhu, Ling-Qiang .
AGING CELL, 2015, 14 (05) :867-877
[42]   Increased Coupling of Caveolin-1 and Estrogen Receptor α Contributes to the Fragile X Syndrome [J].
Yang, Qi ;
Yang, Le ;
Zhang, Kun ;
Guo, Yan-Yan ;
Liu, Shui-Bing ;
Wu, Yu-Mei ;
Li, Xiao-Qiang ;
Song, Qian ;
Zhuo, Min ;
Zhao, Ming-Gao .
ANNALS OF NEUROLOGY, 2015, 77 (04) :618-636
[43]   Regulatory B Subunits of Protein Phosphatase 2A Are Involved in Site-specific Regulation of Tau Protein Phosphorylation [J].
Yu, Un Young ;
Yoo, Byong Chul ;
Ahn, Jung-Hyuck .
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2014, 18 (02) :155-161
[44]   Outcomes of the POG 9340/9341/9342 Trials for Children With High-Risk Neuroblastoma: A Report From the Children's Oncology Group [J].
Zage, Peter E. ;
Kletzel, Morris ;
Murray, Kevin ;
Marcus, Robert ;
Castleberry, Robert ;
Zhang, Yang ;
London, Wendy B. ;
Kretschmar, Cynthia .
PEDIATRIC BLOOD & CANCER, 2008, 51 (06) :747-753